Bagsværd, Denmark, 8 August 2023 – Novo Nordisk today announced the headline results from the SELECT cardiovascular outcomes trial. The double-blinded trial compared subcutaneous once-weekly semaglutide 2.4 mg with placebo as an adjunct to standard of care for prevention of major... Continue Reading
INDIANAPOLIS, Nov. 8, 2023 / PRNewswire / — The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic... Continue Reading
Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in Patients with HeFH to be Presented at the American Heart Association (AHA) Scientific Sessions 2023 on November 12 at 3:30 p.m. ET; Company to Host Investor Event and Webcast on November 12 at 6:30 p.m. ET BOSTON, Nov. 07, 2023... Continue Reading
Palo Alto, Calif. – November 7, 2023 – Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the U.S. Food and Drug Administration (FDA) has approved Recor’s Paradise™... Continue Reading
Dallas, TX. — The American Society for Preventive Cardiology (ASPC) together with Endless Health will be at the American Academy of Family Physicians’ (AAFP) annual conference – Family Medicine Experience (FMX) – in Chicago, IL October 27-29, 2023 – offering attendees... Continue Reading
Since its inception 38 years ago, the American Society for Preventive Cardiology (ASPC) has maintained a robust history of commitment. Established in 1985, the ASPC has consistently prioritized the development of programs aimed at improving both basic and clinical education. Additionally, it has... Continue Reading
Basel, July 07, 2023 — Novartis today announced that the U.S. District Court for the District of Delaware issued a negative decision regarding the validity of a patent covering Entresto and combinations of sacubitril and valsartan, which expires in 2025 with its pediatric exclusivity.... Continue Reading
EAST HANOVER, N.J., July 10, 2023 / PRNewswire / — Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran) to enable earlier use in patients with elevated LDL-C who have an increased risk of heart disease, as an adjunct... Continue Reading
The Woodlands, Texas, May 26, 2023 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration (FDA) has approved INPEFA™ (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart... Continue Reading
Despite the established role of low-density lipoprotein cholesterol (LDL-C) as a major risk factor for cardiovascular disease (CVD), and the persistence of CVD as the leading cause of morbidity and mortality in the United States, national quality assurance metrics no longer include LDL-C... Continue Reading
The Women in Preventive Cardiology (WIPC) working group had our first formal meeting in January 2021 with the purpose “to support and mentor women in preventive cardiology and to advocate for women’s cardiovascular health by promoting optimal treatment and transdisciplinary research to... Continue Reading
